The Study Of The Treatment And Prognostic In The Advanced Non-small Cell Lung Cancer With The Expression Of ERCC1 And BRCA1

Objective: To investigate the Expression of ERCC1,BRCA1 and the correlation with platinum-based chemotherapy Clinical Efficacy and survival in the advanced non-small cell lung cancer. Methods: We have retrospectively studied the 81patients with advanced non-small cell lung cancer from January 2001 to December 2006 using platinum-based chemotherapy as first-line treatment.The tissue was examined by immuno histoche-mical technique.We studied the correlation of the expression of ERCC1,BRCA1and time to progression and overall survial. Methods: The response rate is 50.0% in ERCC1 negative group,which is 27.6% in positive group p=0.047; The response rate is 48.7% in BRCA1 negative group,which is 35.7% in positive group p=0.236.The media survival time of ERCC1 negative group is 20.6 months,which is 12.1months in ERCC1 positive group,p=0.041.There is no significant difference of media survival time in BRCA1 positive group and negative group.; The multivariate analysis found that ps,stages and the expression of ERCC1 are independent prognostic factors affecting overall survival. Conclusion: The results suggests that the expression of ERCC1 could predict the sensitivity in advanced non-small cell lung with paltinum-based chemothempy, and positive expression of ERCC1may predicate possible resistence to platinum-based chemotherapy.The ERCC1 expression have the relation of advanced lung cancer patients with platinum-based chemotherapy in survival. To a certain extent, ERCC1 expression can help determine prognosis of advanced non-small cell lung cancer patients with platinum-based chemotherapy...